MarketCap
Facebook
X
Telegram
Checkmate Pharmaceuticals Market Cap | CMPI
As of November 07, 2026 Checkmate Pharmaceuticals has a market cap of $ 231 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Checkmate Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 52.7 M | 150 M | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 150 M | 52.7 M | 101 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Reata Pharmaceuticals
RETA
|
1.64 B | - | - | $ 6.29 B |  USA |
 |
ObsEva SA
OBSV
|
156 M | - | -15.52 % | $ 10.5 M |  Schweiz |
 |
PolarityTE
PTE
|
4.32 M | - | -0.82 % | $ 1.78 M | USA |
 |
Kronos Bio
KRON
|
69.3 M | - | 1.49 % | $ 50.8 M | USA |
 |
Landos Biopharma
LABP
|
48.1 M | - | 0.58 % | $ 144 M | USA |
 |
Myovant Sciences Ltd.
MYOV
|
1.4 B | - | -0.04 % | $ 2.62 B | USA |
 |
Poseida Therapeutics
PSTX
|
306 M | - | - | $ 857 M | USA |
 |
Trevena
TRVN
|
5.09 M | - | -46.58 % | $ 31.8 M | USA |
 |
Immunovant
IMVT
|
6.49 B | $ 30.5 | 7.43 % | $ 5.56 B | USA |
 |
Virpax Pharmaceuticals
VRPX
|
851 K | - | -45.12 % | $ 2.85 M | USA |
 |
Oncorus
ONCR
|
8.55 K | - | -8.54 % | $ 3.19 M | USA |
 |
Y-mAbs Therapeutics
YMAB
|
216 M | - | - | $ 382 M | USA |
 |
Navidea Biopharmaceuticals
NAVB
|
8.96 M | - | -2.99 % | $ 2.47 M | USA |
 |
InMed Pharmaceuticals
INM
|
5.45 M | $ 14.77 | 13.57 % | $ 61.5 M |  Canada |
 |
Stealth BioTherapeutics Corp
MITO
|
450 M | - | - | $ 23.9 M | USA |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
Satsuma Pharmaceuticals
STSA
|
27.2 M | - | -0.9 % | $ 36.5 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
291 M | $ 1.15 | 3.15 % | $ 98.1 M | USA |
 |
SpringWorks Therapeutics
SWTX
|
4.45 B | - | - | $ 3.48 B | USA |
 |
Metacrine
MTCR
|
13.5 M | - | - | $ 24.2 M | USA |
 |
Turning Point Therapeutics
TPTX
|
2.35 B | - | -0.13 % | $ 3.73 B | USA |
 |
Revolution Medicines
RVMD
|
19.6 B | $ 192.41 | 8.31 % | $ 36.6 B | USA |
 |
Infinity Pharmaceuticals
INFI
|
17 M | - | -46.98 % | $ 3.57 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
17.7 M | - | 31.87 % | $ 1.61 M | USA |
 |
Monopar Therapeutics
MNPR
|
401 M | $ 71.6 | 6.52 % | $ 531 M | USA |
 |
Intellia Therapeutics
NTLA
|
776 M | $ 11.32 | 1.94 % | $ 1.23 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M |  Israel |
 |
Evelo Biosciences
EVLO
|
27 M | - | -14.46 % | $ 27.9 M | USA |
 |
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | USA |
 |
Morphic Holding
MORF
|
1.52 B | - | - | $ 2.42 B | USA |
 |
Novan
NOVN
|
26.2 M | - | -24.84 % | $ 2.64 M | USA |
 |
Genocea Biosciences
GNCA
|
72.7 M | - | -15.0 % | $ 3.04 M | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
3.11 M | - | -9.21 % | $ 2.55 M | USA |
 |
Albireo Pharma
ALBO
|
548 M | - | -0.23 % | $ 916 M | USA |
 |
BELLUS Health
BLU
|
1.7 B | - | - | $ 2.47 B | Canada |
 |
bluebird bio
BLUE
|
3.35 M | - | - | $ 546 M | USA |
 |
Intra-Cellular Therapies
ITCI
|
13.3 B | - | - | $ 13.6 B | USA |
 |
IGM Biosciences
IGMS
|
84.7 M | - | - | $ 76.9 M | USA |
 |
Marinus Pharmaceuticals
MRNS
|
497 M | - | - | $ 29.6 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
211 M | - | - | $ 216 M | USA |
 |
CASI Pharmaceuticals
CASI
|
114 M | - | - | $ 35.4 M | USA |
 |
ContraFect Corporation
CFRX
|
1.08 M | - | -5.16 % | $ 5.39 M | USA |
 |
Sigilon Therapeutics
SGTX
|
39.9 M | - | - | $ 728 M | USA |
 |
Rubius Therapeutics
RUBY
|
11.7 M | - | -33.55 % | $ 7.81 M | USA |
 |
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | USA |
 |
TRACON Pharmaceuticals
TCON
|
5.89 M | - | -1.38 % | $ 46.8 M | USA |
 |
Mirati Therapeutics
MRTX
|
2.56 B | - | - | $ 3.3 B | USA |
 |
Revance Therapeutics
RVNC
|
479 M | - | - | $ 309 M | USA |
 |
Allogene Therapeutics
ALLO
|
545 M | $ 1.03 | -5.5 % | $ 227 M | USA |